SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending due to its anticipated inclusion in the S&P 500, sparking excitement among investors who foresee potential institutional investment and a price surge akin to Palantir's after its inclusion. The community is actively discussing potential short squeezes, target prices, and the impact of the upcoming company summit and potential Federal Reserve rate cuts on the stock's performance. Some investors are cautioning against excessive optimism, citing previous instances where stocks experienced declines post-inclusion.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

SCHD is trending as investors weigh its dividend yield against recent market performance, with some expressing frustration over underperformance compared to growth-focused ETFs. The community is actively debating whether to hold SCHD for long-term income or rotate into higher-growth opportunities, especially as some point to its heavy weighting in energy and healthcare sectors. Recent discussions also highlight anticipation for the next dividend announcement and how broader economic factors like interest rate cuts and potential tariffs might impact the ETF.

Pineapple Financial, Inc. is a Canadian based mortgage technology and brokerage company, which engages in the mortgage brokerage services and technology solutions to Canadian mortgage agents, brokers, sub-brokers, brokerages, and consumers. The company also provides back-office services, together with pre-underwriting support services. The company was founded by Shubha Dasgupta, Kendall Marin, and Charles Andrew Green on October 16, 2015 and is headquartered in North York, Canada.

Pineapple Financial Inc

Pineapple Financial ($PAPL) is trending due to its recent $100 million private placement and strategic move into Injective ($INJ.X) digital assets. The community is actively discussing potential short squeezes and the stock's volatile price action, while also debating the long-term prospects of PAPL given its financial situation. Some traders are wary of dilution, while others see significant upside potential due to the small float and high borrowing costs.

Gyrodyne LLC engages in the management of a portfolio of medical office and industrial properties. Its properties include Flowerfield, Port Jefferson Professional Park, Courtland Medical Center, and Grove. The company was founded by Peter James Papadakos in 1946 and is headquartered in St. James, NY.

Gyrodyne LLC

GYRO is trending due to increased attention on its low float and potential for a significant breakout, with some traders drawing comparisons to other low-float runners. Community members are closely watching key breakout levels, speculating about a potential meme run and a possible short squeeze. Some investors believe the company is undervalued considering recent property sales.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

Infinite Money Glitch ($IMG.X) is trending as the community rallies around its Solana ($SOL.X) reward system for holders, emphasizing passive income and a strong community. The token's resilience and recent sponsorship with Kimbo Slice Jr. are also key talking points, with members highlighting the project's longevity and unique reward structure within the crypto space.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending as chatter revolves around potential acquisition bids and analyst optimism for their drug candidate, AXPAXLI, despite recent market volatility. Community members speculate on buyout prices and partnerships, focusing on the upcoming SOL-1 data and its potential impact on valuation. Some traders are weighing OCUL against competitors in the wet AMD space, while others discuss the broader biotech sector trends.

Aventus

Aventus is trending, with community members highlighting a new partnership with The Truth Network. Bullish sentiment seems to be building with anticipation of a potential listing on a top 10 exchange. Some traders are pointing to the token's low market cap and limited supply as factors that could drive price appreciation.

Procter & Gamble Co. engages in the provision of branded consumer packaged goods. It operates through the following segments: Beauty, Grooming, Health Care, Fabric and Home Care, and Baby, Feminine and Family Care. The Beauty segment offers hair, skin, and personal care. The Grooming segment consists of shave care like female and male blades and razors, pre and post shave products, and appliances. The Health Care segment includes oral care products like toothbrushes, toothpaste, and personal health care such as gastrointestinal, rapid diagnostics, respiratory, and vitamins, minerals, and supplements. The Fabric and Home care segment consists of fabric enhancers, laundry additives and detergents, and air, dish, and surface care. The Baby, Feminine and Family Care segment sells baby wipes, diapers, and pants, adult incontinence, feminine care, paper towels, tissues, and toilet paper. The company was founded by William Procter and James Gamble in 1837 and is headquartered in Cincinnati, OH.

Procter & Gamble Co.

Procter & Gamble is trending as traders discuss its potential upside and key resistance levels, with some eyeing it as a safe haven amid market uncertainty. Community members are actively considering options strategies and anticipating a run toward specific price targets, while also monitoring news related to analyst ratings and potential tariff impacts. Broader discussions involve P&G's role as a defensive stock and its established history of dividend increases.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

Shares of ATYR are active amid ongoing discussions about upcoming data from a Phase 3 trial, with some speculating on a potential catalyst date while others assess the likelihood of success. Bullish sentiment is fueled by employee stock options and new hires, interpreted as confidence in positive results, although some traders are hedging their bets. The community is debating the company's financial moves and the potential impact of positive data on its long-term prospects.

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Beam Therapeutics Inc

BEAM is trending as investors anticipate catalysts related to a September 14th date mentioned frequently across social media, though the specific event is unconfirmed, creating speculation and driving interest. Recent #BeamTherapeutics mentions include discussion around new data, comparisons to Wave Life Sciences ($WVE), and analysts highlighting Beam's base-editing advantages within the broader gene editing space, particularly for AATD.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Acadia (ACAD) Up 26.1% Since Last Earnings Report?

Blueprint Medicines came under pressure from Wall Street on Monday after at least six brokerages downgraded the stock following news of its&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sanofi-to-buy-blueprint-medicines-for-up-to-9.5-billion/chkoCYnRbHc">$9.1 billion acquisition</a> by French pharmaceutical giant Sanofi.The stock closed at $127.79 on Monday, up 26.1% for the day. After-hours trading showed a slight decline of 0.1% to $127.67.TD Cowen analyst Marc Frahm lowered the stock rating to ‘Hold’ from ‘Buy’ and established a price target of $130 based on the acquisition terms.&nbsp;JPMorgan reduced its rating to ‘Neutral’ from ‘Overweight’ and adjusted its target price to $129 from $130.Wolfe Research reduced Blueprint's rating to ‘Peer Perform’ from ‘Outperform’ by noting that the deal values Blueprint at $129 per share.&nbsp;Oppenheimer lowered its stock rating to ‘Perform’ from ‘Outperform,’ while describing the agreement as a “solid outcome for shareholders.”Scotiabank reduced its stock rating to ‘Sector Perform’ from ‘Outperform,’ while establishing a target price of $135.&nbsp;Wedbush assigned a $129 target after downgrading Blueprint to ‘Neutral’, while Needham downgraded it to ‘Hold.’Blueprint Medicines shareholders will receive one non-tradeable contingent value right (CVR), entitling them to two potential milestone payments of $2 and $4 per CVR, contingent on&nbsp;achieving future development and regulatory milestones for BLU-808.BLU-808 is an investigational oral inhibitor targeting wild-type KIT, which plays a role in mast cell activation involved in inflammatory diseases, including chronic urticaria.Including these potential payments, the total equity value of the Sanofi acquisition rises to approximately $9.5 billion on a fully diluted basis.Sanofi CEO Paul Hudson said this acquisition moves their rare and immunology portfolios forward.Sanofi’s earnings and gross margin will benefit from the transaction after 2026, while the company’s financial guidance for 2025 remains unaffected.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.One user described the price movement as a positive surprise, reporting a roughly 30% gain on their investment,&nbsp;noting this was better than recent returns on SpringWorks Therapeutics, but lower than several earlier buyouts this year.&nbsp;<stembedurl>https://stocktwits.com/Jackie_O_/message/616535057</stembedurl>Another user said that increased European pharma purchases of U.S. companies might be a strategy to gain favor with the Trump administration.<stembedurl>https://stocktwits.com/ajmore/message/616481051</stembedurl>Blueprint Medicines’&nbsp;stock has risen 46.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Blueprint Medicines company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Blueprint Medicines Stock  Lands Several Downgrades After Sanofi’s Buyout Deal, But Retail Bulls Keep The Faith

Analysts revised price targets near the deal’s $129-per-share valuation.

Equity

Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines 

Shares of Blueprint Medicines Corporation (BPMC) traded 26% higher in pre-market on Monday after French pharmaceutical company Sanofi (SNY) <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.sanofi.com/en/media-room/press-releases/2025/2025-06-02-05-00-00-3091541">announced</a> that it would acquire Blueprint in a bid to expand its rare immunological disease portfolio.Under the terms of the deal, Sanofi will pay $129 per share in cash at closing, representing an equity value of approximately $9.1 billion.The upfront purchase price represents a 27% premium to Blueprint’s closing price on Friday of $101.35.In addition, Blueprint shareholders will receive one non-tradable contingent value right (CVR), which will entitle them to receive two potential milestone payments of $2 and $4 per CVR for the achievement of future milestones for BLU-808, an investigational therapy with the potential to treat a broad range of diseases in immunology.The total equity value of the transaction, including potential CVR payments, represents approximately $9.5 billion on a fully diluted basis, Sanofi said. The firm added that it expects the transaction to be completed in the third quarter of 2025.The acquisition includes Ayvakit or Ayvakyt (Avapritinib), the only approved medicine for rare immunology diseases, advanced and indolent systemic mastocytosis (ASM &amp; ISM), in addition to Elenestinib, an investigational medicine for systemic mastocytosis, as well as BLU-808.Sanofi CEO Paul Hudson said that the company retains a “sizeable capacity” for further acquisitions. The firm expects the Blueprint acquisition not to have a significant impact on its financial guidance for 2025 but to be immediately accretive to gross margin and to business operating income and EPS after 2026.Last month, Sanofi said it is looking to invest at least $20 billion in the U.S. through 2030. The company also announced it would acquire U.S.-based Vigil Neuroscience, Inc. (VIGL) for about $470 million soon after.On Stocktwits, retail sentiment around Blueprint Medicines Corporation jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:627/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_02_at_8_06_38_AM_png_dab4b84360.webp" alt="BPMC's Sentiment Meter and Message Volume as of 8:15 a.m. ET on June 2, 2025 | Source: Stocktwits" width="627" height="66"><figcaption>BPMC's Sentiment Meter and Message Volume as of 8:15 a.m. ET on June 2, 2025 | Source: Stocktwits</figcaption></figure>Meanwhile, retail sentiment around Sanofi stayed unmoved within the ‘bullish’ territory while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:630/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_02_at_8_14_54_AM_png_d728df50b2.webp" alt="SNY's Sentiment Meter and Message Volume as of 8:15 a.m. ET on June 2, 2025 | Source: Stocktwits" width="630" height="65"><figcaption>SNY's Sentiment Meter and Message Volume as of 8:15 a.m. ET on June 2, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user believes U.S. pharmaceutical companies will receive acquisition offers from their European counterparts.<stembedurl>https://stocktwits.com/ajmore/message/616481051</stembedurl>While <a href="https://stocktwits.com/symbol/BPMC">BPMC stock</a> is up by about 16% this year, <a href="https://stocktwits.com/symbol/SNY">SNY stock</a> is up by over 2%.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/microsoft-commits-400-million-to-boost-swiss-ai-cloud-ecosystem/chkoUr7RbHb">Microsoft Commits $400M To Boost Swiss AI, Cloud Ecosystem: Retail Mood Stays ‘Bearish’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Photo taken on April 15, 2025 shows the pharmaceutical factory of pharmaceutical company Sanofi in Hangzhou, Zhejiang province, China. (Photo credit should read CFOTO/Future Publishing via Getty Images)

Sanofi To Buy Blueprint Medicines For Up To $9.5B: Retail Sees More Acquisition Offers From European Pharma Companies

Sanofi will pay $129 per share in cash at closing, representing a 27% premium to Blueprint’s closing price on Friday of $101.35.

Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results

Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results PR Newswire CAMBRIDGE, Mass., Feb. 13, 2025 -- Achieved...

Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025

Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025 Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on...

Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth

Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth PR Newswire CAMBRIDGE...

Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire CAMBRIDGE, Mass...

Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting

Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting Blueprint Medicines' Continued Leadership in Redefining...

Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst

JP Morgan initiates coverage on Blueprint Medicines, highlighting Ayvakit's significant growth, 2024 revenue forecast, and potential strategic opportunities.

 Latest Ratings for BPMC...

Blueprint Medicines Corp. is a precision therapy company, which engages in the provision of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

BPMC
Blueprint Medicines Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BPMC News

BPMC Blueprint Medicines Corp